The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening

European Urology

Volumn 58, Issue 4, 2010, Pages 482-484

  Ficarra, Vincenzo ^a   Novara, Giacomo ^a   Zattoni, Filiberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; DEMOGRAPHY; HUMAN; INCIDENCE; NOTE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

EID: 77956549484     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.07.025     Document Type: Editorial

References (19)

1. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80
2. J.O. Ung, J.P. Richie, M.H. Chen, A.A. Renshaw, and A.V. D'Amico Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era Urology 60 2002 458 463
3. V. Ficarra, G. Novara, and A. Galfano Precursor isoform of prostate-specific antigen and human kallikrein 2: two new promising biomarkers for the unsolved challenge of early prostate cancer detection Eur Urol 55 2009 556 559
4. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
5. K. Fall, H. Garmo, O. Andrén Scandinavian Prostate Cancer Group Study No. 4 Prostate-specific antigen levels as a predictor of lethal prostate cancer J Natl Cancer Inst 99 2007 526 532
6. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
7. K.A. Landers, M.J. Burger, and M.A. Tebay Use of multiple biomarkers for a molecular diagnosis of prostate cancer Int J Cancer 114 2005 950 956
8. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
9. PCA3 -based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 16
10. V. Vlaeminck-Guillem, A. Ruffion, J. André, M. Devonec, and P. Paparel Urinary prostate cancer 3 test: toward the age of reason? Urology 75 2010 447 453
11. J. Ruiz-Aragon, and S. Marquez-Pelaez Assessment of the PCA3 test for prostate cancer diagnosis. A systematic review and meta-analysis Actas Urol Esp 34 2010 346 355
12. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535
13. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
14. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
15. M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
16. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809
17. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975 1978
18. D.G. Bostwick, V.E. Gould, and J. Qian Prostate cancer detected by uPM3: radical prostatectomy findings Mod Pathol 19 2006 630 633
19. M.P. van Gils, D. Hessels, and C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215 1222